Literature DB >> 18253722

On the analysis of ligand-directed signaling at G protein-coupled receptors.

Frederick J Ehlert1.   

Abstract

The phenomenon of "ligand-directed signaling" is often considered to be inconsistent with the traditional receptor theory. In this review, I show how the mathematics of the receptor theory can be used to measure the observed affinity and relative efficacy of protean ligands at G protein-coupled receptors. The basis of this analysis rests on the assumption that the fraction of agonist bound in the form of the active receptor-G protein-guanine nucleotide complex is the biochemical equivalent of the pharmacological stimulus. Consequently, this stimulus function is analogous to the current response of a ligand-gated ion channel. Because guanosine triphosphate (GTP) greatly inhibits the formation of the active quaternary complex, even the most efficacious agonists probably only elicit partial receptor activation, and it seems likely that the ceiling of 100% receptor activation is not reached in the intact cell with high intracellular concentrations of GTP. Under these conditions, the maximum of the stimulus function is proportional to the ratio of microscopic affinity constants of the agonist for ground and active states. Ligand-directed signaling depends on the existence of different active states of the receptor with different selectivities for different G proteins or other effectors. This phenomenon can be characterized using classic pharmacological methods. Although not widely appreciated, it is possible to estimate the product of observed affinity and intrinsic efficacy expressed relative to that of another agonist (intrinsic relative activity) through the analysis of the concentration-response curves. No other information is required. This approach should be useful in quantifying agonist activity and in converting the two disparate parameters of potency and maximal response into a single parameter dependent only on the agonist-receptor-effector complex.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18253722     DOI: 10.1007/s00210-008-0260-4

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  84 in total

1.  Stimulus amplification, efficacy, and the operational model. Part I--binary complex occupancy mechanisms.

Authors:  J P Trzeciakowski
Journal:  J Theor Biol       Date:  1999-06-07       Impact factor: 2.691

2.  Stimulation of guanosine 5'-O-(3-[35S] thiotriphosphate) binding by cholinergic muscarinic receptors in membranes of rat olfactory bulb.

Authors:  M C Olianas; P Onali
Journal:  J Neurochem       Date:  1996-12       Impact factor: 5.372

Review 3.  Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors.

Authors:  Terry Kenakin
Journal:  Trends Pharmacol Sci       Date:  2007-07-13       Impact factor: 14.819

4.  Identification of rat brain muscarinic M4 receptors coupled to cyclic AMP using the selective antagonist muscarinic toxin 3.

Authors:  M C Olianas; A Adem; E Karlsson; P Onali
Journal:  Eur J Pharmacol       Date:  1998-09-18       Impact factor: 4.432

5.  Receptor and betagamma binding sites in the alpha subunit of the retinal G protein transducin.

Authors:  R Onrust; P Herzmark; P Chi; P D Garcia; O Lichtarge; C Kingsley; H R Bourne
Journal:  Science       Date:  1997-01-17       Impact factor: 47.728

6.  Seven helix receptors are enzymes catalysing G protein activation. What is the agonist Kact?

Authors:  M Waelbroeck; L Boufrahi; S Swillens
Journal:  J Theor Biol       Date:  1997-07-07       Impact factor: 2.691

7.  Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs.

Authors:  Jason D Kilts; Hilary S Connery; Elaine G Arrington; Mechelle M Lewis; Cindy P Lawler; Gerry S Oxford; Karen L O'Malley; Richard D Todd; Bonita L Blake; David E Nichols; Richard B Mailman
Journal:  J Pharmacol Exp Ther       Date:  2002-06       Impact factor: 4.030

8.  Differential involvement of intracellular domains of the rat NTS1 neurotensin receptor in coupling to G proteins: a molecular basis for agonist-directed trafficking of receptor stimulus.

Authors:  Delphine Skrzydelski; Anne-Marie Lhiaubet; Antony Lebeau; Patricia Forgez; Misa Yamada; Emmanuel Hermans; William Rostene; Didier Pelaprat
Journal:  Mol Pharmacol       Date:  2003-08       Impact factor: 4.436

9.  Type II adenylylcyclase integrates coincident signals from Gs, Gi, and Gq.

Authors:  K D Lustig; B R Conklin; P Herzmark; R Taussig; H R Bourne
Journal:  J Biol Chem       Date:  1993-07-05       Impact factor: 5.157

10.  Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens.

Authors:  Philippe De Deurwaerdère; Sylvia Navailles; Kelly A Berg; William P Clarke; Umberto Spampinato
Journal:  J Neurosci       Date:  2004-03-31       Impact factor: 6.167

View more
  36 in total

1.  Identification of the first biased NPS receptor agonist that retains anxiolytic and memory promoting effects with reduced levels of locomotor stimulation.

Authors:  Stewart D Clark; Terrence P Kenakin; Steven Gertz; Carla Hassler; Elaine A Gay; Tiffany L Langston; Rainer K Reinscheid; Scott P Runyon
Journal:  Neuropharmacology       Date:  2017-03-03       Impact factor: 5.250

2.  Biased agonism as a mechanism for differential signaling by chemokine receptors.

Authors:  Sudarshan Rajagopal; Daniel L Bassoni; James J Campbell; Norma P Gerard; Craig Gerard; Tom S Wehrman
Journal:  J Biol Chem       Date:  2013-10-21       Impact factor: 5.157

3.  Analysis of functional responses at G protein-coupled receptors: estimation of relative affinity constants for the inactive receptor state.

Authors:  Frederick J Ehlert; Michael T Griffin; Hinako Suga
Journal:  J Pharmacol Exp Ther       Date:  2011-05-16       Impact factor: 4.030

4.  Analysis of agonism and inverse agonism in functional assays with constitutive activity: estimation of orthosteric ligand affinity constants for active and inactive receptor states.

Authors:  Frederick J Ehlert; Hinako Suga; Michael T Griffin
Journal:  J Pharmacol Exp Ther       Date:  2011-05-16       Impact factor: 4.030

5.  Quantifying ligand bias at seven-transmembrane receptors.

Authors:  Sudarshan Rajagopal; Seungkirl Ahn; David H Rominger; William Gowen-MacDonald; Christopher M Lam; Scott M Dewire; Jonathan D Violin; Robert J Lefkowitz
Journal:  Mol Pharmacol       Date:  2011-05-24       Impact factor: 4.436

6.  Angiotensin and biased analogs induce structurally distinct active conformations within a GPCR.

Authors:  Laura M Wingler; Meredith A Skiba; Conor McMahon; Dean P Staus; Alissa L W Kleinhenz; Carl-Mikael Suomivuori; Naomi R Latorraca; Ron O Dror; Robert J Lefkowitz; Andrew C Kruse
Journal:  Science       Date:  2020-02-21       Impact factor: 47.728

7.  Bias analyses of preclinical and clinical D2 dopamine ligands: studies with immediate and complex signaling pathways.

Authors:  Tarsis F Brust; Michael P Hayes; David L Roman; Kevin D Burris; Val J Watts
Journal:  J Pharmacol Exp Ther       Date:  2014-12-24       Impact factor: 4.030

8.  Estimation of ligand affinity constants for receptor states in functional studies involving the allosteric modulation of G protein-coupled receptors: implications for ligand bias.

Authors:  Frederick J Ehlert; Michael T Griffin
Journal:  J Pharmacol Toxicol Methods       Date:  2014-01-13       Impact factor: 1.950

9.  Estimation of relative microscopic affinity constants of agonists for the active state of the receptor in functional studies on M2 and M3 muscarinic receptors.

Authors:  John A Tran; Alexander Chang; Minoru Matsui; Frederick J Ehlert
Journal:  Mol Pharmacol       Date:  2008-11-07       Impact factor: 4.436

10.  Selectivity of agonists for the active state of M1 to M4 muscarinic receptor subtypes.

Authors:  Katherine W Figueroa; Michael T Griffin; Frederick J Ehlert
Journal:  J Pharmacol Exp Ther       Date:  2008-09-29       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.